Miranda Weston-Smith

Miranda Weston-Smith

Miranda helps early stage biomedical businesses to attract investment and develop their business strategy. Miranda founded and runs BioBeat, a programme to inspire the next wave of bioentrepreneurs and business leaders

Telephone: +44 (0)1223 511 664
Address: St John's Innovation Centre, Cowley Road, Cambridge
Postcode: CB4 0WS
Country: United Kingdom
Website: http://www.mws-consulting.co.uk/
Membership type:Professional Individual and Corporate < 5 (£50+VAT pa)

Miranda is a Coach for the SME Instrument of the European Commission, Business Mentor for entrepreneurship programmes in the University of Cambridge and contributes to the University of Cambridge Masters in Bioscience Enterprise course. She is a member of the Department of Zoology Alumni and Fundraising Committee of the University of Cambridge and an Advisor to the Rising Network.

She brings experience as a Technology Transfer Manager at Cambridge Enterprise, University of Cambridge, where she assessed and marketed life science technologies, negotiated licences, and spun-out companies. She was responsible for technology transfer at the University of Cambridge for the Cambridge-MIT Institute. In her five years at the seed capital firm, Cambridge Research and Innovation, she identified and invested in early stage technologies. Miranda co-founded Cambridge Network with Hermann Hauser.

Miranda holds an MA (Cantab) in Natural Sciences, is a Fellow of the Linnean Society and holds the Chartered Institute of Management Accounting’s Diploma in Management Accounting. She has edited eight books and contributes to industry publications.



BioBeat connects entrepreneurs with the leaders in biotech. Get involved and grow a strong business

Biobeat 18 logo

BioBeat unveils 2018’s 50 Movers and Shakers

A new report released today unveils 50 female leaders in healthcare business in the UK. Produced by BioBeat, 50 Movers and Shakers in BioBusiness 2018 emphasises the current role of women in leading, inspiring and innovating to ensure new technologies and treatments continue to improve UK research, health and society.*

1 November 2018Read in full